Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial

Next Previous
Trial Profile

Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Convalescent anti-SARS-CoV-2 plasma (Primary) ; Hydroxychloroquine (Primary) ; Sarilumab (Primary)
  • Indications COVID 2019 infections; COVID-19 pneumonia
  • Focus Therapeutic Use
  • Acronyms CCAP; CCAP-RCT

Most Recent Events

  • 30 Sep 2020 Status changed from recruiting to discontinued.
  • 29 Jul 2020 Planned number of patients changed from 1500 to 1100.
  • 27 May 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top